Liraglutide Effects on Epicardial Fat Inflammatory Genes

NCT03260881 on ClinicalTrials.gov · last registry update 2025-07-08

Finished 5 September 2024, after enrolling 38 people. Primary outcome, as filed: EAT Inflammation. liraglutide is already approved in the US for cardiovascular disease and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Miami
Sponsor type: Other
Enrollment: 38
Started: 2018-09-01
Primary completion: 2024-09-05 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

EAT Inflammation

Conditions studied

Type2 Diabetes · Coronary Artery Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.